GlaxoSmithKline Studies Three-in-One Emphysema Medicine to Keep Ahead of the Pack

Published: Sep 05, 2012

GlaxoSmithKline Plc (GSK), maker of Advair, the world’s best-selling drug for smoker’s cough and asthma, is considering a three-in-one treatment delivered in a single device to stay ahead of competitors such as Novartis AG. (NOVN) Glaxo is exploring the next steps for its experimental GSK961081 drug, which combines two different types of treatments that help open up the airways in a single molecule for patients who have emphysema or chronic bronchitis from smoking, said Darrell Baker, head of the company’s respiratory drug development. The double-duty molecule may allow Glaxo to develop a triple-therapy for hard-to-treat patients delivered through a single device, which has not yet been done.

Back to news